Characteristics, outcomes, and mortality amongst 133,589 patients with prevalent autoimmune diseases diagnosed with, and 48,418 hospitalised for COVID-19 : a multinational distributed network cohort analysis
Tan, Eng Hooi (Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford)
Sena, Anthony G. (Department of Medical Informatics, Erasmus University Medical Center (Holanda))
Prats-Uribe, Albert (University of Oxford. Centre for Statistics in Medicine)
You, Seng Chan (Department of Biomedical Informatics, Ajou University School of Medicine (Corea))
Ahmed, Waheed-Ul-Rahman (College of Medicine and Health, University of Exeter)
Kostka, Kristin (Real World Solutions (Estats Units d'Amèrica))
Reich, Christian (Real World Solutions (Estats Units d'Amèrica))
Duvall, Scott L. (Department of Internal Medicine, University of Utah School of Medicine)
Lynch, Kristine E. (Department of Internal Medicine, University of Utah School of Medicine)
Matheny, Michael E. (Department of Biomedical Informatics, Vanderbilt University Medical Center)
Duarte-Salles, Talita 1985- (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Bertolin, Sergio Fernandez (Institut Universitari d'Investigació en Atenció Primària Jordi Gol)
Hripcsak, George (New York-Presbyterian Hospital)
Natarajan, Karthik (New York-Presbyterian Hospital)
Falconer, Thomas (Columbia University. Department of Biomedical Informatics)
Spotnitz, Matthew (Columbia University. Department of Biomedical Informatics)
Ostropolets, Anna (Columbia University. Department of Biomedical Informatics)
Blacketer, Clair (Department of Medical Informatics, Erasmus University Medical Center (Holanda))
Alshammari, Thamir (Medication Safety Research Chair, King Saud Univeristy)
Alghoul, Heba (Faculty of Medicine, Islamic University of Gaza)
Alser, Osaid (Massachusetts General Hospital (Boston))
Lane, Jennifer C. E. (Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford)
Dawoud, Dalia M. (Cairo University, Faculty of Pharmacy, Cairo, Egypt)
Shah, Karishma (Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford)
Yang, Yue (DHC Technologies)
Zhang, Lin (Melbourne School of Population and Global Health, The University of Melbourne, Victoria 3015, Australia)
Areia, Carlos (Nuffield Department of Clinical Neurosciences, University of Oxford)
Golozar, Asieh (Departament of Epidemiology, Johns Hopkins School of Public)
Relcade, Martina (Universitat Autònoma de Barcelona)
Casajust, Paula (Trial Form Support (Barcelona))
Jonnagaddala, Jitendra (School of Public Health and Community Medicine (Austràlia))
Subbian, Vignesh (College of Engineering, The University of Arizona Tucson)
Vizcaya, David (Bayer Pharmaceuticals (Barcelona))
Lai, Lana Y. H. (School of Medical Sciences, University of Manchester)
Nyberg, Fredrik (School of Public Health and Community Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg (Suècia))
Morales, Daniel R. (Division of Population Health Sciences, University of Dundee)
Posada, Jose D. (Stanford Center for Biomedical Informatics Research, Department of Medicine, School of Medicine, Stanford University)
Shah, Nigam H. (Stanford Center for Biomedical Informatics Research, Department of Medicine, School of Medicine, Stanford University)
Gong, Mengchun (Health Management Institute, Southern Medical University)
Vivekanantham, Arani (Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford)
Abend, Aaron (Autoimmune Registry (Regne Unit))
Minty, Evan P. (O'Brien School for Public Health, Faculty of Medicine, University of Calgary)
Suchard, Marc (Department of Biostatistics, University of California)
Rijnbeek, Peter (Department of Medical Informatics, Erasmus University Medical Center (Holanda))
Ryan, Patrick B. (Department of Biomedical Informatics, Columbia University)
Prieto-Alhambra, Daniel (Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford)
Universitat Autònoma de Barcelona

Data:	2020
Resum:	Patients with autoimmune diseases were advised to shield to avoid COVID-19, but information on their prognosis is lacking. We characterised 30-day outcomes and mortality after hospitalisation with COVID-19 among patients with prevalent autoimmune diseases, and compared outcomes after hospital admissions among similar patients with seasonal influenza. Multinational network cohort study Electronic health records data from Columbia University Irving Medical Center (CUIMC) (NYC, United States [US]), Optum [US], Department of Veterans Affairs (VA) (US), Information System for Research in Primary Care-Hospitalisation Linked Data (SIDIAP-H) (Spain), and claims data from IQVIA Open Claims (US) and Health Insurance and Review Assessment (HIRA) (South Korea). All patients with prevalent autoimmune diseases, diagnosed and/or hospitalised between January and June 2020 with COVID-19, and similar patients hospitalised with influenza in 2017-2018 were included. 30-day complications during hospitalisation and death We studied 133,589 patients diagnosed and 48,418 hospitalised with COVID-19 with prevalent autoimmune diseases. The majority of participants were female (60. 5% to 65. 9%) and aged ≥50 years. The most prevalent autoimmune conditions were psoriasis (3. 5 to 32. 5%), rheumatoid arthritis (3. 9 to 18. 9%), and vasculitis (3. 3 to 17. 6%). Amongst hospitalised patients, Type 1 diabetes was the most common autoimmune condition (4. 8% to 7. 5%) in US databases, rheumatoid arthritis in HIRA (18. 9%), and psoriasis in SIDIAP-H (26. 4%). Compared to 70,660 hospitalised with influenza, those admitted with COVID-19 had more respiratory complications including pneumonia and acute respiratory distress syndrome, and higher 30-day mortality (2. 2% to 4. 3% versus 6. 3% to 24. 6%). Patients with autoimmune diseases had high rates of respiratory complications and 30-day mortality following a hospitalization with COVID-19. Compared to influenza, COVID-19 is a more severe disease, leading to more complications and higher mortality. Future studies should investigate predictors of poor outcomes in COVID-19 patients with autoimmune diseases.
Ajuts:	European Commission 806968
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	COVID-19 ; Autoimmune condition ; Mortality ; Hospitalisation ; Open science ; OHDSI ; OMOP
Publicat a:	medRxiv, november 2020

DOI: 10.1101/2020.11.24.20236802
PMID: 33269355

25 p, 727.1 KB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats